PR Newswire is a global leader in communications and marketing services, enabling organizations to connect and engage with their target audiences worldwide.
Recent Articles By The Author
Data At ASH 2016 Show Strong, Lasting Efficacy Of IMBRUVICA® (ibrutinib) Through Five Years Of Treatment For Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
89% of study patients, including those with high-risk CLL/SLL, responded to therapy
In Clinical Trials, CAR T Cell Immunotherapy Continues To Yield Complete Responses In Children & Young Adults With Relapsed And Refractory Leukemia
--At ASH Meeting, CHOP Researchers Report on Global Multicenter Trial and Pilot Trial of Innovative Leukemia Treatments--